Viking Global Investors
RPRX icon

Viking Global Investors’s Royalty Pharma RPRX Stock Holding History

Viking Global Investors’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,597,460
Closed -$93.6M – 93
2025
Q2 		$93.6M Sell
2,597,460
-7,966,479
-75% -$264M 0.27% 69
2025
Q1 		$329M Sell
10,563,939
-1,643,946
-13% -$52.1M 1.04% 40
2024
Q4 		$311M Buy
12,207,885
+113,864
+0.9% +$3.02M 1.01% 37
2024
Q3 		$342M Buy
12,094,021
+123,963
+1% +$3.43M 1.25% 26
2024
Q2 		$316M Buy
11,970,058
+484,511
+4% +$13.4M 1.21% 28
2024
Q1 		$349M Buy
11,485,547
+1,398,130
+14% +$41.2M 1.3% 25
2023
Q4 		$283M Buy
10,087,417
+623,216
+7% +$17.1M 1.04% 33
2023
Q3 		$257M Sell
9,464,201
-386,731
-4% -$11.5M 1.04% 31
2023
Q2 		$303M Sell
9,850,932
-1,353,317
-12% -$45.8M 1.24% 29
2023
Q1 		$404M Buy
11,204,249
+1,195,738
+12% +$44.3M 1.89% 20
2022
Q4 		$396M Sell
10,008,511
-873,083
-8% -$36.4M 1.98% 20
2022
Q3 		$437M Sell
10,881,594
-1,489,100
-12% -$63.6M 2.02% 18
2022
Q2 		$520M Buy
12,370,694
+1,606,222
+15% +$65.8M 2.38% 15
2022
Q1 		$419M Buy
10,764,472
+449,094
+4% +$17.6M 1.7% 20
2021
Q4 		$411M Buy
10,315,378
+6,174,870
+149% +$240M 1.18% 27
2021
Q3 		$150M Buy
4,140,508
+901,854
+28% +$35M 0.41% 62
2021
Q2 		$133M Buy
3,238,654
+1,176,901
+57% +$50.1M 0.4% 55
2021
Q1 		$89.9M Sell
2,061,753
-225,247
-10% -$10.7M 0.27% 71
2020
Q4 		$114M Buy
2,287,000
+338,936
+17% +$14.4M 0.31% 67
2020
Q3 		$82M Sell
1,948,064
-566,921
-23% -$24.3M 0.3% 65
2020
Q2 		$122M Buy
+2,514,985
New +$124M 0.53% 49

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Viking Global Investors's RPRX Position: Q3 2025 in Review

Viking Global Investors sold out of Royalty Pharma (RPRX) in Q3 2025, closing a stake of 2,597,460 shares — an estimated $93.6M sold.

Viking Global Investors first reported a position in RPRX in Q2 2020 and held it in 21 quarters. The position peaked at $520M in Q2 2022. 487 funds tracked by Wall St. Rank hold RPRX as of Q3 2025.

  • Viking Global Investors reported no remaining Royalty Pharma position as of Q3 2025 after selling out during the quarter.
  • Viking Global Investors sold 2,597,460 Royalty Pharma shares in Q3 2025, an estimated $93.6M.
  • Viking Global Investors first reported a position in Royalty Pharma in Q2 2020 and held it in 21 quarters.
  • Viking Global Investors's Royalty Pharma position peaked at $520M in Q2 2022.
  • 487 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2025.

Based on Viking Global Investors's 13F filing for Q3 2025, filed 14 Nov 2025.